13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

27 trials found

diseases per page:

Showing 1 to 10 of 27 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-002500-91-SE (EUCTR)	01/06/2017	27/06/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic ...
2	EUCTR2015-002500-91-HR (EUCTR)	13/06/2016	06/07/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
3	EUCTR2015-002500-91-PT (EUCTR)	06/06/2016	13/04/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis. - Open Lab ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCI Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
4	EUCTR2015-002500-91-LT (EUCTR)	31/05/2016	17/03/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
5	EUCTR2015-002500-91-LV (EUCTR)	20/04/2016	19/02/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	Germany;New Zealand;Sweden;Georgia;Bulgaria;Romania;Croatia;Poland;Belgium;Hungary;United Kingdom;Li ...
6	EUCTR2015-002500-91-EE (EUCTR)	04/04/2016	07/03/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
7	EUCTR2015-002500-91-IT (EUCTR)	09/02/2016	22/01/2021	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCL Product Name: 1.0mg ...	CELGENE INTERNATIONAL II SàRL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
8	EUCTR2015-002500-91-SK (EUCTR)	22/01/2016	28/10/2015	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United Kingdom;Hungary;Belgium;Poland;Croatia;Romania;Georgia;Bulgaria;Germany;New Zealand;Sweden;Uk ...
9	EUCTR2015-002500-91-PL (EUCTR)	20/01/2016	01/12/2015	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Colom ...
10	EUCTR2015-002500-91-BG (EUCTR)	13/01/2016	20/10/2015	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	South Africa;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Lithuania;United Kingdom;Hungary;Bel ...

First Previous1 2 3Next Last